Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-27
2008-05-27
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S562000, C530S351000, C424S009100, C424S085100, C424S085200, C424S085400
Reexamination Certificate
active
11097146
ABSTRACT:
A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of reductive glutathione in macrophages.
REFERENCES:
patent: 4871528 (1989-10-01), Tognella et al.
patent: 5087453 (1992-02-01), Strassmann
patent: 5214062 (1993-05-01), Mark et al.
patent: H1427 (1995-04-01), Briet et al.
patent: 5441976 (1995-08-01), Andersson et al.
patent: 5476966 (1995-12-01), Andersson et al.
patent: 5488040 (1996-01-01), Jamas et al.
patent: 5541162 (1996-07-01), Ohmori et al.
patent: 5580577 (1996-12-01), Herzenberg et al.
patent: 5627152 (1997-05-01), Kenyhercz et al.
patent: 5747459 (1998-05-01), Rowe et al.
patent: 5762922 (1998-06-01), Noble et al.
patent: 5766873 (1998-06-01), Noble et al.
patent: 5804582 (1998-09-01), Andersson et al.
patent: 6077828 (2000-06-01), Abbruzzese et al.
patent: 6197749 (2001-03-01), Hamuro et al.
patent: 2005/0239886 (2005-10-01), Hamuro et al.
patent: 0 501 641 (1992-09-01), None
patent: 0 638 588 (1995-02-01), None
patent: 0 715 853 (1996-06-01), None
patent: WO 91/18594 (1991-12-01), None
patent: WO 95/06465 (1995-03-01), None
M. Roederer, et al., “CD4 and CD8 T Cells with High Intracellular Glutathione Levels are Selectively Lost as the HIV Infection Progresses”, International Immunology, vol. 3, No. 9, pp. 933-937, 1991.
E. Sherwood, et al., “Enhancement of Interleukin 1 and Interleukin 2 Production by Soluble Glucan”, Int. J. Immunopharmacol., vol. 9, No. 3, pp. 261-268, Abstract.
S. Tsuyyuki, et al., XP-002223987, “Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma”, Clinical Immunology and Immunopathology, vol. 88, No. 2, Aug. 1998, pp. 192-198.
J. Peterson, et al., XP-002223988, “Glutathione Levels in Antigen-Presenting Cells Modulate Th1 Versus Th2 Response Patterns”, Proceedings of the National Academy of the Sciences of the United States, vol. 95, No. 6, Mar. 17, 1998, pp. 3071-3076.
M. Sato, et al., XP-002067027, “Antioxidants Inhibit Tumor Necrosis Factor-α Mediated Stimulation of Interleukin-8, Monocyte Chemoattractant Protein-1, and Collagenase Expression in Cultured Human Synovial Cells”, The Journal of Rheumatology, 1996, vol. 23, No. 3, pp. 432-438.
R. Ruffmann, et al., XP-001051483, “GSH Rescue by N-Acetylcystein”, Klin Wochenschr, 1991, vol. 69, pp. 857-862.
J. Hamuro, XP-001120690, “Lentinan Regulates the Local Inflammatory Cellular Reaction at Tumor Tissues-Its Relation with Antitumor Effects”, Biotherapy, vol. 10, No. 4, Apr. 1996, pp. 581-588.
M. Anderson, XP-002223989, “Glutathione: An Overview of Biosynthesis and Modulation”, Chemico-Biological Interactions, 111-112, 1998, pp. 1-14.
P. Parodi, XP-000750365, “A Role for Milk Proteins in Cancer Prevention”, The Australian Journal of airy Technology, vol. 53, Apr. 1998, pp. 37-47.
J. Hamuro, et al., XP-009002330, “The Triggering and Healing of Tumor Stromal Inflammatory Reactions By Oxidative and Reductive Macrophages”, Gann Monograph on Cancer Research, vol. 48, 1999, pp. 153-164.
C. Yim, et al., “Use of N-Acetyl Cysteine to Increases Intracellular Glutathione During the Induction of Antitumor Responses by IL-21”, Journal of Immunology, vol. 152, No. 12, 1994, pp. 5796-5805.
K. Dobashi, et al., “Regulation of LPS Induced IL-12 Production by IFN-γ and IL-4 through Intracellular Glutathione Status in Human Alveolar Macrophages”, Clin. Exp. Immunol., 2001, vol. 124, pp. 290-296.
H. Minhas, et al., “Comparison of th Delivery of Reduced Glutathione into P388D, Cells by Reduced Glutathione and Its Mono- and Diethyl Ester Derivatives”, Biochemical Pharmacology, vol. 49, No. 10, 1995, pp. 1475-1782, XP002234498.
E. Sherwood, et al., “Enhancement of Interleukin 1 and Interleukin 2 Production by Soluble Glucan”, Int. J. Immunopharmacol., vol. 9, No. 3, pp. 261-268, Abstract, 1987.
Hamuro Junji
Murata Yukie
Ajinomoto Co. Inc.
Kam Chih-Min
LandOfFree
Method of suppressing immune response by reducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of suppressing immune response by reducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of suppressing immune response by reducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3937833